MoonLake Immunotherapeutics
MLTX
$16.47
-$0.03-0.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 46.96M | 46.46M | 41.97M | 41.98M | 38.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 268.34M | 267.37M | 244.84M | 229.20M | 200.88M |
| Operating Income | -268.34M | -267.37M | -244.84M | -229.20M | -200.88M |
| Income Before Tax | -264.15M | -258.39M | -229.71M | -213.30M | -178.74M |
| Income Tax Expenses | 1.08M | 1.08M | 611.00K | 404.00K | 381.00K |
| Earnings from Continuing Operations | -265.22 | -259.47 | -230.32 | -213.70 | -179.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1.56M | 2.39M | 3.00M | 3.20M | 2.96M |
| Net Income | -263.67M | -257.08M | -227.32M | -210.50M | -176.16M |
| EBIT | -268.34M | -267.37M | -244.84M | -229.20M | -200.88M |
| EBITDA | -265.10M | -264.29M | -242.22M | -226.97M | -199.04M |
| EPS Basic | -3.83 | -3.87 | -3.52 | -3.33 | -2.79 |
| Normalized Basic EPS | -2.38 | -2.39 | -2.18 | -2.06 | -1.72 |
| EPS Diluted | -3.83 | -3.87 | -3.52 | -3.33 | -2.79 |
| Normalized Diluted EPS | -2.38 | -2.39 | -2.18 | -2.06 | -1.72 |
| Average Basic Shares Outstanding | 276.53M | 265.89M | 257.85M | 252.96M | 252.48M |
| Average Diluted Shares Outstanding | 276.53M | 265.89M | 257.85M | 252.96M | 252.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |